Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07447557 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of Intrathecal ELP-02 for Charcot-Marie-Tooth Disease Type 4J (CMT4J)

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date changed from estimate of Jul 2026 to Aug 7, 2026v3
  2. Primary and study completion pushed from Dec 2031 to Dec 2032v2 Show 4 more changesShow less
    • Recruitment opened
    • Start date: Apr 2026 to Jul 2026
    • Study sites: 0 to 2
    • Eligibility criteria expanded, about 3 words
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
First-in-human Phase 1/2, open-label study to evaluate the safety, tolerability, and efficacy of a single lumbar intrathecal dose of ELP-02 to individuals with CMT4J.
Trial Details
NCT Number NCT07447557
Lead Sponsor Elpida Therapeutics SPC
Conditions
(from sponsor)		 Charcot-Marie-Tooth Disease Type 4J
Related terms Charcot-Marie-Tooth Disease, Type 4j
Enrollment 8 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov